{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:54:50Z","timestamp":1794542090076,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, adult patients with FOP were randomized to garetosmab, an activin A-blocking antibody (<jats:italic>n<\/jats:italic>\u2009=\u200920) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u200924) in period 1 (28 weeks), followed by an open-label period 2 (28 weeks; <jats:italic>n<\/jats:italic>\u2009=\u200943). The primary end points were safety and for period 1, the activity and size of HO lesions. All patients experienced at least one treatment-emergent adverse event during period 1, notably epistaxis, madarosis and skin abscesses. Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out. The primary efficacy end point in period 1 (total lesion activity by PET\u2013CT) was not met (<jats:italic>P<\/jats:italic>\u2009=\u20090.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; <jats:italic>P<\/jats:italic>\u2009=\u20090.0027). Further investigation of garetosmab in FOP is ongoing. ClinicalTrials.gov identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03188666\">NCT03188666<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02561-8","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:02:40Z","timestamp":1695916960000},"page":"2615-2624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"given":"Maja","family":"Di Rocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-8156","authenticated-orcid":false,"given":"Eduardo","family":"Forleo-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Pignolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Orcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Kolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-6959","authenticated-orcid":false,"given":"Annalisa","family":"Madeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Bubbear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Tabarkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szczepanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-209X","authenticated-orcid":false,"given":"Javier","family":"Bachiller-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Dahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esm\u00e9e","family":"Botman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter G.","family":"Raijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Mukaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Tile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Portal-Celhay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijie","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret J.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Boyapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-7537","authenticated-orcid":false,"given":"Kusha","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3991-2177","authenticated-orcid":false,"given":"Scott J.","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6508-8942","authenticated-orcid":false,"given":"Aris N.","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinko Gonzalez","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"DelGizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5399-676X","authenticated-orcid":false,"given":"E. Marelise W.","family":"Eekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2561_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-80","volume":"6","author":"RJ Pignolo","year":"2011","unstructured":"Pignolo, R. J., Shore, E. M. & Kaplan, F. S. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J. Rare Dis. 6, 80 (2011).","journal-title":"Orphanet J. Rare Dis."},{"key":"2561_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat, G. et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J. Rare Dis. 12, 123 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"2561_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2572-9411\/2020\/2.1196","volume":"5","author":"M Liljesthrom","year":"2020","unstructured":"Liljesthrom, M., Pignolo, R. J. & Kaplan, F. S. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J. Rare Dis. Res Treat. 5, 31\u201336 (2020).","journal-title":"J. Rare Dis. Res Treat."},{"key":"2561_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bone.2012.07.002","volume":"51","author":"A Morales-Piga","year":"2012","unstructured":"Morales-Piga, A. et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone 51, 748\u2013755 (2012).","journal-title":"Bone"},{"key":"2561_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo, R. J. et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J. Rare Dis. 16, 350 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"2561_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1068-7","volume":"14","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo, R. J. et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J. Rare Dis. 14, 98 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"2561_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan, F. S. et al. Fibrodysplasia ossificans progressiva. Best. Pr. Res Clin. Rheumatol. 22, 191\u2013205 (2008).","journal-title":"Best. Pr. Res Clin. Rheumatol."},{"key":"2561_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11832-015-0704-6","volume":"9","author":"F Ortiz-Agapito","year":"2015","unstructured":"Ortiz-Agapito, F. & Colmenares-Bonilla, D. Quality of life of patients with fibrodysplasia ossificans progressiva. J. Child Orthop. 9, 489\u2013493 (2015).","journal-title":"J. Child Orthop."},{"key":"2561_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2106\/00004623-199302000-00008","volume":"75","author":"RB Cohen","year":"1993","unstructured":"Cohen, R. B. et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J. Bone Jt. Surg. Am. 75, 215\u2013219 (1993).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"2561_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan, F. S. et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J. Bone Jt. Surg. Am. 92, 686\u2013691 (2010).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"2561_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","volume":"101","author":"FS Kaplan","year":"2017","unstructured":"Kaplan, F. S., Al Mukaddam, M. & Pignolo, R. J. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone 101, 123\u2013128 (2017).","journal-title":"Bone"},{"key":"2561_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bone.2017.09.014","volume":"109","author":"RJ Pignolo","year":"2018","unstructured":"Pignolo, R. J. & Kaplan, F. S. Clinical staging of fibrodysplasia ossificans progressiva (FOP). Bone 109, 111\u2013114 (2018).","journal-title":"Bone"},{"key":"2561_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore, E. M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet 38, 525\u2013527 (2006).","journal-title":"Nat. Genet"},{"key":"2561_CR14","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell, S. J. et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med 7, 303ra137 (2015).","journal-title":"Sci. Transl. Med"},{"key":"2561_CR15","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/jbmr.3235","volume":"32","author":"J Upadhyay","year":"2017","unstructured":"Upadhyay, J. et al. The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent. J. Bone Min. Res 32, 2489\u20132499 (2017).","journal-title":"J. Bone Min. Res"},{"key":"2561_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","volume":"109","author":"DM Alessi Wolken","year":"2018","unstructured":"Alessi Wolken, D. M., Idone, V., Hatsell, S. J., Yu, P. B. & Economides, A. N. The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva. Bone 109, 210\u2013217 (2018).","journal-title":"Bone"},{"key":"2561_CR17","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino, K. et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc. Natl Acad. Sci. USA 112, 15438\u201315443 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2561_CR18","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald, L. E. et al. Precise and in situ genetic humanization of 6\u2009Mb of mouse immunoglobulin genes. Proc. Natl Acad. Sci. USA 111, 5147\u20135152 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2561_CR19","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153\u20135158 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2561_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1281-4","volume":"15","author":"F Robert","year":"2020","unstructured":"Robert, F., Desroches-Castan, A., Bailly, S., Dupuis-Girod, S. & Feige, J. J. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J. Rare Dis. 15, 4 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"2561_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ajhg.2013.07.004","volume":"93","author":"WL Wooderchak-Donahue","year":"2013","unstructured":"Wooderchak-Donahue, W. L. et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am. J. Hum. Genet 93, 530\u2013537 (2013).","journal-title":"Am. J. Hum. Genet"},{"key":"2561_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2019.03.009","volume":"124","author":"E Botman","year":"2019","unstructured":"Botman, E. et al. Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [(18)F]NaF PET\/CT study. Bone 124, 1\u20136 (2019).","journal-title":"Bone"},{"key":"2561_CR23","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00198-012-2049-z","volume":"23","author":"D Bauer","year":"2012","unstructured":"Bauer, D. et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos. Int. 23, 2425\u20132433 (2012).","journal-title":"Osteoporos. Int."},{"key":"2561_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran, S. et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin. Chem. Lab. Med. 49, 1271\u20131274 (2011).","journal-title":"Clin. Chem. Lab. Med."},{"key":"2561_CR25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jcph.1638","volume":"60","author":"F Vanhoutte","year":"2020","unstructured":"Vanhoutte, F. et al. Pharmacokinetics and Pharmacodynamics of garetosmab (anti-activin a): results from a first-in-human phase 1 study. J. Clin. Pharm. 60, 1424\u20131431 (2020).","journal-title":"J. Clin. Pharm."},{"key":"2561_CR26","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield, S. B. et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw. Open 4, e2033457 (2021).","journal-title":"JAMA Netw. Open"},{"key":"2561_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/jcsm.12639","volume":"11","author":"D Rooks","year":"2020","unstructured":"Rooks, D. et al. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J. Cachexia Sarcopenia Muscle 11, 1525\u20131534 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2561_CR28","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-10-0468","volume":"16","author":"LM Kenny","year":"2010","unstructured":"Kenny, L. M. et al. Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin. Cancer Res. 16, 4236\u20134245 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2561_CR29","first-page":"633","volume":"33","author":"RA Hawkins","year":"1992","unstructured":"Hawkins, R. A. et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J. Nucl. Med. 33, 633\u2013642 (1992).","journal-title":"J. Nucl. Med."},{"key":"2561_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2967\/jnumed.106.037200","volume":"49","author":"FD Grant","year":"2008","unstructured":"Grant, F. D. et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med. 49, 68\u201378 (2008).","journal-title":"J. Nucl. Med."},{"key":"2561_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bcp.13777","volume":"85","author":"EC Hsiao","year":"2019","unstructured":"Hsiao, E. C. et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br. J. Clin. Pharm. 85, 1199\u20131207 (2019).","journal-title":"Br. J. Clin. Pharm."},{"key":"2561_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/JTO.0000000000000569","volume":"10","author":"B Keam","year":"2015","unstructured":"Keam, B. et al. Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation. J. Thorac. Oncol. 10, 1189\u20131194 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"2561_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02872-2","volume":"9","author":"JB Lees-Shepard","year":"2018","unstructured":"Lees-Shepard, J. B. et al. Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva. Nat. Commun. 9, 471 (2018).","journal-title":"Nat. Commun."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02561-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02561-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02561-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:09:06Z","timestamp":1699970946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02561-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2561"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02561-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.R. is a principal investigator (PI) of Regeneron Pharmaceuticals and Ipsen trials. E.F.-N., C.P.-C., N.S., P.H., B.J.M., A.B., K.M., S.J.M., A.J.R., A.N.E., D.G.T., G.A.H., S.J.O., R.D., D.M.W. and G.D.Y. are employees of and hold stocks and shares in Regeneron Pharmaceuticals. R.J.P. is a PI of the Regeneron Pharmaceuticals LUMINA-1 and Clementia\/Ipsen MOVE trials; a founding member and immediate past president of the International Clinical Council on FOP; and chair of the International Clinical Council Publications Committee. R.K. is a PI of clinical trials sponsored by Clementia\/Ipsen and Regeneron Pharmaceuticals and is a non-paid member of the International Clinical Council on FOP and IFOPA registry advisory board. P.O. is a PI of clinical trials sponsored by Regeneron Pharmaceuticals. T.F.-B. is a sub-investigator of the Regeneron Pharmaceuticals LUMINA-1 trial and PI of IPSEN FALKON trial. C.R. has received research grants to their institution from Regeneron Pharmaceuticals. S.K. is a sub-investigator of the Regeneron Pharmaceuticals LUMINA-1 trial. A.M. is a sub-investigator in clinical trials sponsored by Regeneron Pharmaceuticals and Clementia-Ipsen. J.S.B. is a sub-investigator of the Regeneron Pharmaceuticals LUMINA-1 and Clementia\/Ipsen MOVE trials. J.T. received grants to their institution (University Rzesz\u00f3w) as a speaker for Merck and Novartis, and is a hired scientific expert for SoftSystem. M.S. is a speaker for Roche. J.B.-C. is an investigator of a clinical trial sponsored by Regeneron Pharmaceuticals. A.M.C. received a grant to their institution (University Health Network) for a clinical trial. K.M.D. is a PI on the Regeneron Pharmaceuticals LUMINA-1 trial. This project was supported by CTSA award no. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors\/sponsor and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. E.B. is a sub-investigator of the Regeneron Pharmaceuticals LUMINA-1 trial at Amsterdam UMC, The Netherlands. P.G.R. is a sub-investigator of the Regeneron Pharmaceuticals LUMINA-1 trial at Amsterdam UMC, The Netherlands. M.A.M. is a PI of clinical trials sponsored by Clementia\/Ipsen, Regeneron Pharmaceuticals and Incyte; and is a non-paid member of the International Clinical Council on FOP and IFOPA registry advisory board. L.T. received a grant to their institution (University Health Network) for a clinical trial (as a sub-investigator). E.M.W.E. receives subsidies\/financing FOP research from the Dutch FOP Patient Foundation, IFOPA, Regeneron Pharmaceuticals, EU-IMI (AZ) and Clementia\/Ipsen; holds non-paid board memberships for the International Clinical Council on FOP, IFOPA registry advisory board, Dutch Society for Endocrinology (NVE) BoNe; is a representative for Amsterdam Bone Center and Rare Bone Expert Center, European FOP consortium investigators; is a member of the ERN BOND and ASBMR committee; and is lead clinical PI on the Regeneron Pharmaceuticals LUMINA-1 trial. F.S.K. is a founding member and past president of the International Clinical Council on FOP; a member of the Medical Advisory Board of the IFOPA Global Registry; and a global PI on the Regeneron Pharmaceuticals LUMINA-1 and the Clementia\/Ipsen MOVE trials.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}